RATIONALE: Allergic rhinitis (AR) is a common allergy increasing in incidence in developed countries. Better understanding of pathogenesis can provide better management and prevention. METHODS: We employed our Search Tag Analyze Resource platform to conduct meta-analysis using the National Center for Biotechnology's Gene Expression Omnibus to define AR pathogenesis. We tagged 74 AR nasal mucosa and 146 blood samples, using 58 and 148 healthy nasal epithelium and blood samples, respectively, as controls. We then analyzed the signature in Ingenuity Pathway Analysis, restricting genes that showed statistical significance (p<0.05) and an absolute experimental log ratio greater than 0.10 between disease and control samples. RESULTS: Nasal mucosa analysis revealed choline degradation and fatty acid b-oxidation as top canonical pathways. The receptor tyrosine kinase EFNA1 and the fatty b-oxidation enzyme AOXC1 were top upstream regulators. Loss of epithelial barrier integrity and airway inflammation were suggested by upregulation of the protease inhibitor CTS1, intelectin 1, eosinophil lysophospholipase, and gasdermin B. Interferon-g, a key Th1 effector, response was reduced through downregulation of effector genes such as NLRP2B, GBP6, and IFI44L. Blood analysis revealed Th2, OX40, and CDK5 signaling as top canonical pathways. Top upstream regulators included transcription factors TCFL72 and BCL6, and CD3. We found upregulation of known drivers of atopy including IL17RB and serglycin. Additionally, anti-inflammatory mediators such as p27, SCGB1C1, and FGL2 were downregulated. Lastly, our analysis suggested arsenic trioxide, known to alleviate airway hypersensitivity, as potential drug therapy. CONCLUSIONS: These results elucidate the roles of immunomodulatory metabolites and mediators, and epithelial airway integrity in AR pathogenesis. RESULTS: Proteomic analysis revealed that following S. chartarum exposure, 29% of the 3,915 detected proteins were differentially expressed compared to AOC; whereas 13% of 3,176 proteins were altered after A. versicolor exposure and 7% of 2,152 proteins were altered following A. fumigatus (7%) exposure. Comparative analysis identified 11 proteins that were in common with all 3 fungal exposures, including ARHGDIB and COTL1, known to be involved in tissue morphology and antifungal defense, respectively. Additional associations were identified with neurological and immunological disease, and with inflammatory responses. The Aspergillus species shared only 4 proteins, whereas S. chartarum shared 10-fold more proteins with each Aspergillus species. Also involved in immunological disease, IPA predicted that 27 miRNAs, common to all 3 fungal exposures, regulated the 11 identified proteins. CONCLUSIONS: While exposure to individual fungal species influences multiple host response mechanisms, common proteins could be identified to serve as potential biomarkers for fungal exposure. These results identified additional proteins and miRNAs in fungal exposure that have not been previously reported. National Institute of Environmental Health Sciences, Research Triangle Park, NC. RATIONALE: Antigenic determinants on mite allergen Der p 2 were analyzed to identify IgE antibody binding sites that can be modified to produce hypoallergens for immunotherapy. METHODS: The structure of the epitope for the murine IgG mAb 7A1 that overlaps with human IgE was identified by determining the X-ray crystal structure of Der p 2.0103 in complex with the mAb 7A1-Fab and by nuclear magnetic resonance (NMR) using a 7A1-single-chain variable fragment (scFv). Two rDer p 2 epitope double mutants were expressed in Pichia pastoris and purified by affinity chromatography. Two anti-Der p 2 IgE antibody constructs with the same variable regions were expressed as Fab in Escherichia coli and as scFab in P. pastoris. Both were based on a specific scFv isolated from a combinatorial phage display library constructed from a mite allergic patient. Antibody binding was measured by immunoassays. RESULTS: The structure of Der p 2 in complex with mAb 7A1-Fab was determined by X-ray crystallography at 2.45 A resolution. NMR results confirmed structural changes in the allergen due to binding 7A1-scFv. Two sets of allergen epitope double mutants bound mAb 1D8 (that recognizes a site opposite from mAb 7A1 epitope) but showed reduced binding, versus the wild type, of mAb 7A1, IgE from allergic subjects and the two IgE recombinant antibody constructs. Therefore, the mutated residues were involved in IgE antibody binding. CONCLUSIONS: Mutagenesis analysis of a Der p 2 epitope defined by X-ray crystallography revealed an IgE antibody binding site that will be considered for the design of hypoallergens for immunotherapy.
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